Anacor Pharms Inc patents expiration
1. Eucrisa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8039451 | ANACOR PHARMS INC | Boron-containing small molecules |
Jun, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9682092 | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Feb, 2027
(2 years from now) | |
| US8501712 | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Feb, 2027
(2 years from now) | |
|
US9682092 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Aug, 2027
(3 years from now) | |
|
US8501712 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Aug, 2027
(3 years from now) | |
|
US8039451 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules |
Dec, 2029
(5 years from now) | |
| US8168614 | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Jan, 2030
(5 years from now) | |
|
US8168614 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Jul, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-191) | Apr 03, 2026 |
| New Chemical Entity Exclusivity(NCE) | Dec 14, 2021 |
| Pediatric Exclusivity(PED) | Sep 23, 2023 |
| New Patient Population(NPP) | Mar 23, 2023 |
Drugs and Companies using CRISABOROLE ingredient
NCE-1 date: 23 September, 2022
Market Authorisation Date: 14 December, 2016
Treatment: Method of treating mild to moderate atopic dermatitis.
Dosage: OINTMENT;TOPICAL
EUCRISA family patents
2. Kerydin patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9572823 | ANACOR PHARMS INC | Boron-containing small molecules |
Feb, 2026
(1 year, 9 months from now) | |
| US9566289 | ANACOR PHARMS INC | Boron-containing small molecules |
Feb, 2026
(1 year, 9 months from now) | |
| US9566290 | ANACOR PHARMS INC | Boron-containing small molecules |
Feb, 2026
(1 year, 9 months from now) | |
| US9549938 | ANACOR PHARMS INC | Boron-containing small molecules |
Feb, 2026
(1 year, 9 months from now) | |
|
US9566290 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules |
Aug, 2026
(2 years from now) | |
|
US9572823 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules |
Aug, 2026
(2 years from now) | |
|
US9566289 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules |
Aug, 2026
(2 years from now) | |
|
US9549938 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules |
Aug, 2026
(2 years from now) | |
| US7767657 | ANACOR PHARMS INC | Boron-containing small molecules |
May, 2027
(3 years from now) | |
| US7582621 | ANACOR PHARMS INC | Boron-containing small molecules |
May, 2027
(3 years from now) | |
|
US7582621 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules |
Nov, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 07, 2019 |
| Pediatric Exclusivity(PED) | Jan 07, 2020 |
Drugs and Companies using TAVABOROLE ingredient
NCE-1 date: 07 January, 2019
Market Authorisation Date: 07 July, 2014
Treatment: Treatment of onychomychosis of a toenail caused by trichophyton rubrum or trichophyton mentagrophytes; Treatment of onychomycosis of a toenail; Treatment for onychomycosis that is tinea unguium
Dosage: SOLUTION;TOPICAL
KERYDIN family patents